The Angiotensin II Type 2 (AT2) Receptor Promotes Axonal Regeneration in the Optic Nerve of Adult Rats by Lucius, Ralph et al.
 
661
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/08/661/10 $2.00
Volume 188, Number 4, August 17, 1998 661–670
http://www.jem.org
 
The Angiotensin II Type 2 (AT
 
2
 
) Receptor Promotes
Axonal Regeneration in the Optic Nerve of Adult Rats
 
By Ralph Lucius,
 
*
 
 Stefan Gallinat,
 
‡§
 
 Philip Rosenstiel,
 
*
 
Thomas Herdegen,
 
‡
 
 Jobst Sievers,
 
*
 
 and Thomas Unger
 
‡§
 
From the 
 
*
 
Institute of Anatomy and the 
 
‡
 
Institute of Pharmacology, Christian-Albrechts-University 
Kiel, D-24105 Kiel, Germany; and the 
 
§
 
German Institute for High Blood Pressure Research, 
69120 Heidelberg, Germany
 
Summary
 
The renin-angiotensin system (RAS) has been traditionally linked to blood pressure and vol-
ume regulation mediated through the angiotensin II (ANG II) type 1 (AT
 
1
 
) receptor. Here we
report that ANG II via its ANG II type 2 (AT
 
2
 
) receptor promotes the axonal elongation of
postnatal rat retinal explants (postnatal day 11) and dorsal root ganglia neurons in vitro, and,
moreover, axonal regeneration of retinal ganglion cells after optic nerve crush in vivo. In reti-
nal explants, ANG II (10
 
2
 
7
 
–10
 
2
 
5
 
 M) induced neurite elongation via its AT
 
2
 
 receptor, since the
effects were mimicked by the AT
 
2
 
 receptor agonist CGP 42112 (10
 
2
 
5
 
 M) and were entirely
abolished by costimulation with the AT
 
2
 
 receptor antagonist PD 123177 (10
 
2
 
5
 
 M), but not by
the AT
 
1
 
 receptor antagonist losartan (10
 
2
 
5
 
 M). To investigate whether ANG II is able to pro-
mote axonal regeneration in vivo, we performed optic nerve crush experiments in the adult
rats. After ANG II treatment (0.6 nmol), an increased number of growth-associated protein
(GAP)-43–positive fibers was detected and the regenerating fibers regularly crossed the lesion
site (1.6 mm). Cotreatment with the AT
 
2
 
 receptor antagonist PD 123177 (6 nmol), but not
with the AT
 
1
 
 receptor antagonist losartan (6 nmol), completely abolished the ANG II–induced
axonal regeneration, providing for the first time direct evidence for receptor-specific neu-
rotrophic action of ANG II in the central nervous system of adult mammals and revealing a
hitherto unknown function of the RAS.
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T
 
he renin–angiotensin system (RAS)
 
1
 
 is phylogeneti-
cally one of the oldest hormone systems. Renin, an
acid protease generating the angiotensin peptides, was dis-
covered one hundred years ago, but only recently two an-
giotensin receptor subtypes, designated AT
 
1
 
 (angiotensin II
type 1) and AT
 
2
 
 (angiotensin II type 2), were cloned. The
established actions of angiotensin II (ANG II) within blood
pressure control and body fluid homeostasis as well as the
growth-promoting effects of this peptide in several organs
have been clearly assigned to the AT
 
1
 
 receptor subtype (for
review see reference 1). With the help of highly selective
receptor ligands (2) it is now possible to functionally char-
acterize the second receptor subtype, AT
 
2
 
, and thus to un-
veil major aspects of the RAS that have escaped our recog-
nition in the past, such as the role of AT
 
2
 
 receptor in
growth control and cell differentiation (3–6). AT
 
2
 
 receptors
are abundantly present during development in brain and
peripheral tissues but recede after birth (7–9). In adult indi-
viduals, the AT
 
1
 
 receptor dominates in most organs with
few exceptions, but AT
 
2
 
 receptors can be drastically upreg-
ulated upon tissue injury, for instance in the heart after myo-
cardial infarction (10) and in nervous tissue after central
nervous system (CNS) lesion (11) or axotomy in sciatic
nerves and dorsal root ganglia (DRG) neurons (12). These
observations, together with previous reports on AT
 
2
 
 recep-
tor–induced antiproliferative actions (3–6, 13), neuronal
differentiation in PC12W- (6, 14, 15) and NG108-15 cells
(16), and cellular damage in PC12W- (17) and ovarian
granulosa cells (18), suggest a role of this receptor in cellu-
lar programs of regeneration after neuronal axon injury.
Immature mammalian CNS possesses the ability to re-
generate (19), whereas adult CNS neurons are in most cases
 
1
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unable to reinnervate their target regions after injury, prob-
ably due to the actions of inhibitory molecules from CNS
myelin (20). However, it has been shown that CNS neu-
rons are able to regenerate new processes over long dis-
tances and to reinnervate their target region (21, 22) if they
are supplied with growth-promoting substrates, e.g., trans-
plants of fetal CNS tissue (23) or peripheral nerves (24).
These observations, in conjunction with the above-men-
tioned evidence for AT
 
2
 
 receptor–mediated neuronal dif-
ferentiation, prompted us to investigate the potential role
of ANG II, acting through the AT
 
2
 
 receptor, as a neu-
rotrophic factor in vitro and in vivo.
In the retina, a local RAS with high ANG II levels has
been described (25) and related to the modulation of cal-
cium currents of retinal ganglion cells (RGCs) (26). Adult
retinal explants have frequently been used for in vitro stud-
ies of axonal regeneration (e.g., 27, 28). The results pre-
sented here demonstrate that ANG II promotes both the
neurite elongation of RGCs and DRG
 
 
 
in vitro and the ax-
onal regeneration of RGCs after optic nerve crush in vivo
via its AT
 
2
 
 receptor. Thus, these results are the first to as-
sign a new role for the AT
 
2
 
 receptor in neuronal regenera-
tion and after lesion in the CNS of adult mammals.
 
Materials and Methods
 
Preparation of Retinal Explants.
 
Rat retinal explants (postnatal
day 11) were prepared as previously described (30). In brief, the
eyes were dissected and the retinae were prepared and collected
in L-15 medium (Biochrom KG, Berlin, Germany). Retinal ex-
plants were punched out with a sharpened syringe needle (400-
 
m
 
m diameter) and collected before plating in L-15 medium. All
preparations were carried out at 4
 
8
 
C.
 
Three-dimensional Culture System/Bioassay.
 
The retinal explants
were cultured in a fibrin gel (fibrinogen concentration 
 
z
 
3 mg/
ml) in serum-free medium, supplemented with 0.5 mg/ml
amino-
 
n
 
-caproic acid (Sigma, München, Germany) as a plasmin
inhibitor to prevent destruction of the fibrin gel as previously de-
scribed (30). After precoating coverslips with 10 
 
m
 
l (3 NIH units)
thrombin (Topostasin
 
Ò
 
; Hoffmann La Roche, Basel, Switzer-
land), a 20-
 
m
 
l drop of fibrinogen was given on the coverslip to
start coagulation of the fibrin gel. The retinal explants were
placed in the gel just before coagulation and were cultivated for 3 d
in 24-well plates (Costar, Bodenheim, Germany), filled with 2 ml
of serum-free culture medium at 37
 
8
 
C in humidified CO
 
2
 
/air
(7.5:92.5%).
 
Evaluation of Neurite Outgrowth.
 
After 3 d in vitro, the explant
cultures were fixed in 2.5% glutaraldehyde by microwave irradia-
tion (10 s at 50
 
8
 
C), dehydrated in ethanol, stained with sudan
black (1 min of microwave irradiation at 50
 
8
 
C), and embedded in
a mixture of glycerol and gelatin. Neurite outgrowth of RGCs
was assessed using a computerized image analysis system (Analysis;
SIS, Münster, Germany). The axonal domain of the retinal ex-
plant was plotted by connecting the tips of the outgrown neu-
rites, and the area of the solid retinal explant was subtracted. The
axonal domain was expressed as a percentage of control cultures
(control
 
 5 
 
100%).
 
Preparation of DRG Neurons.
 
Newborn rat DRG were dis-
sected after removal of the dorsal skin, muscles, and the vertebral
arches. The spinal ganglia were picked carefully and washed thor-
oughly in PBS and dissociated in PBS with 0.1% trypsin and 0.1%
collagenase at 37
 
8
 
C for 15 min, followed by a second enzymatic
dissociation step with 0.5% trypsin solution (37
 
8
 
C for 10 min).
After centrifugation (5 min, 500 
 
g
 
), the cell pellet was resus-
pended in DMEM with 10% FCS with the following supple-
ments: 2 mM 
 
l
 
-glutamine, 10 ng/ml nerve growth factor
(Sigma), 50 IU/ml penicillin, and 50 
 
m
 
g/ml streptomycin. Cells
were mechanically dissociated in this culture medium by gentle
pipetting through siliconized Pasteur pipettes with decreasing in-
ner diameter, filtered through a nylon mesh (35 
 
m
 
m pore size),
and preplated in 100-mm culture dishes (Sarstedt, Inc., Newton,
NC) for 2 h. This neuron-enriched cell suspension was plated on
laminin-coated coverslips (5 
 
m
 
g/ml; Sigma) at a density of 2,000
cells/cm
 
2
 
. At appropriate times the cells were fixed in phosphate-
buffered 2.5% glutaraldehyde.
 
Schwannoma Cell Cultures.
 
Schwannoma cells were cultivated
in DMEM with 10% FCS. The confluent monolayer was rinsed
in fresh medium, removed with a rubber policeman, and centri-
fuged (10 min, 40 
 
g
 
) for the preparation of cell pellets.
 
Addition of ANG II and Selective Receptor Agonists and Antago-
nists.
 
ANG II (Bachem, Bubendorf, Switzerland) was dissolved
in DMEM to yield stock solutions of 10
 
2
 
3
 
 M. Losartan (AT
 
1
 
 re-
ceptor antagonist, a gift from Dr. R. Smith, DuPont Merck Phar-
maceutical Company, Wilmington, DE), PD123177 (AT
 
2
 
 receptor
antagonist, a gift from Dr. D. Taylor, Parke Davis Pharmaceutical
Research, Ann Arbor, MI), and CGP 42112 (AT
 
2
 
 receptor ago-
nist, a gift from Dr. M. DeGasparo, Ciba-Geigy Pharmaceutical
Division, Basel, Switzerland) were prepared from 10
 
2
 
3
 
 M stock
solutions in DMEM. All substances were freshly prepared and
later diluted to the desired working concentrations.
 
Surgery.
 
Adult female Wistar rats (180–200 g) were used for
the optic nerve crush experiments. After deep anesthesia by an
intraperitoneal injection of chloral hydrate (400 mg/kg), we ex-
posed the optic nerve through a supraorbital approach as previ-
ously described (23). The optic nerve was crushed 
 
z
 
2 mm be-
hind its bulbar exit using fine forceps for 10 s. After transection of
the rectus superior muscle, a collagen foam (Lysostypt
 
Ò
 
) soaked
with 0.6 nmol ANG II alone or in combination with the AT
 
1
 
 or
AT
 
2
 
 receptor antagonists (6 nmol) was introduced into the vitre-
ous body after a scleral incision. Schwannoma cell pellets were
implanted in an identical manner. After wound closure, the ani-
mals were allowed to survive for 14 d. Five animals served as op-
erated control and five received the collagen foam only to ex-
clude unspecific effects. After each operation, the retinal blood
supply was controlled by indirect ophthalmoscopy to verify that
the central retinal artery was not damaged by the crush lesion
and, thus, that the physiologic blood supply after optic nerve
crush was unaffected.
 
Immunohistochemistry.
 
The rats were killed by transcardiac
perfusion with 4% paraformaldehyde in PBS, and the left optic
nerve was removed. Paraffin-embedded optic nerves were stained
for (
 
a
 
) growth associated protein (GAP)-43 immunoreactivity to
label regenerating axons, (
 
b
 
) neurofilament (clone RT 97) for the
detection of other axons, and (
 
c
 
) glial fibrillary acidic protein
(GFAP) to demonstrate the glial reaction at the lesion site. 7-
 
m
 
m
sections were incubated in 0.75% BSA solution in PBS for 20
min to block unspecific binding, washed three times in PBS, and
incubated for 1 h with a monoclonal rabbit GAP-43 antiserum
(Sigma; 1:400), a neurofilament antibody (clone RT 97; Boeh-
ringer, Mannheim, Germany; 1:100), or GFAP antibody (Boeh-
ringer; 1:50). After washing in PBS (3 times for 10 min), the
sections were incubated with peroxidase-conjugated rabbit anti–
mouse secondary antibody (Sigma; 1:100) for 30 min, washed, 
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and stained with goat anti–rabbit IgG (Sigma; 1:200, 30 min), be-
fore processing with diaminobenzidine and embedding in
Aquatek (Merck, Inc., Hawthorne, NY). Sections were photo-
graphed with a microscope (Axioplan; Carl Zeiss, Inc., Thorn-
wood, NY) on Kodak TMAX 100 (Eastman Kodak Co., Roch-
ester, NY).
 
Reverse Transcriptase PCR Analysis.
 
Total RNA from retinae
and optic nerves after crush was isolated and reverse transcribed ac-
cording to the manufacturer’s recommended protocols (GIBCO
BRL, Eggenstein, Germany). For determination of AT
 
2
 
 receptor
mRNA expression 3, 8, and 14 d after lesion with respect to the
housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase), the reverse transcriptase (RT)-PCR assay was thor-
oughly established as previously described (14) to confirm that the
RT-PCR precisely reflects relative changes in the respective AT
 
2
 
receptor levels. In brief, for experiments with respect to the
housekeeping gene GAPDH, the reaction mixture was equally
split into two tubes before specific primers and PCR reagents
were added. To optimize the RT-PCR assay, the relationship of
signal strength to the number of PCR cycles and the amount of
input cDNA was assessed for AT
 
2
 
 receptors and GAPDH for op-
tic nerves as well as for retinae. For AT
 
2
 
 receptor PCR, 25 ampli-
fication cycles were used for retinae and optic nerves, whereas 17
and 20 cycles, respectively, were used for GAPDH. Under the
experimental conditions used, the signals increased linearly when
increasing amounts of cDNA were subjected to PCR accurately
reflecting relative differences in the respective cDNA levels.
Each reaction mixture was denatured at 95
 
8
 
C for 5 min and
samples were amplified in a programmable thermal controller
(PTC-100; MJ Research Inc., Watertown, MA) using specific
AT
 
1
 
 and AT
 
2
 
 primers. For amplification of AT
 
1
 
, the sense primer
d(TGTAAGATTGCTTCAGCCAGC) and the antisense primer
d(GCCCTGTCCACAATATCTGC) were used. The sense
primer for AT
 
2 
 
receptor PCR d(TTGCTGCCACCAGCA-
GAAAC) was used in combination with the antisense primer
d(GTGTGGGCCTCCAAACCATTGCTA) generating a 1,179-bp
product. Aliquots of each sample were subjected to electrophore-
sis on 1.2% agarose gels and were stained with ethidium bromide.
The identity of PCR products was verified by Southern blot hy-
bridization using 
 
32
 
P-labeled probes according to manufacturer’s
recommendations (Stratagene, Heidelberg, Germany). Hybridiza-
tions were carried out in a RapidHyb solution (Amersham,
Braunschweig, Germany) and washed to stringencies of 0.1 
 
3
 
SSPE/0.1% SDS at 60
 
8
 
C. For hybridization, an AT
 
1
 
 and AT
 
2
 
cDNA (3) was used as probe.
 
Statistics.
 
Statistical comparison of the data was performed us-
ing one-way analysis of variance (ANOVA) followed by an ap-
propriate post-hoc test (Bonferroni). 
 
P 
 
#
 
0.05 was considered sig-
nificant. Further details of statistical analysis are given in the
legends to the figures.
 
Results
 
In Vitro Effects of ANG II on the Neurite Elongation of Rat
Retinal Explants.
 
To study the effects of ANG II on neu-
rite elongation, we prepared retinae from postnatal day 11
rats (29, 30), which are comparable to adult animals in their
regenerative response, and thus represent an appropriate
model for the study of neuronal regeneration. After 3 d in
vitro, there were many regenerating but short neurites visi-
ble in control explants, which grew up to 200 
 
m
 
m out of
the whole circumference of the retinal explants (Fig. 1 
 
a
 
).
Staining with antibodies against Thy-1.1 (31) confirmed
that the regenerating neurites were processes of RGCs
(data not shown). The responsiveness of RGCs to neu-
rotrophic factors was verified by treatment with brain-
derived neurotrophic factor (BDNF; 10 ng/ml), a known
neurotrophic factor for RGCs (27) (Figs. 1, 
 
b
 
, and 2).
Compared with control cultures (100%), BDNF elongated
the neurites up to 160% (
 
6 
 
3%, SEM,
 
 n 
 
5 
 
36). Most of the
RGCs extended their axons for 
 
.300 mm, some of them
up to 500 mm.
The addition of ANG II to the retinal explants dose-
dependently (1025–27 10 M, data not shown) enhanced the
length and number of regenerating neurites. In a concen-
tration of 1026 M, ANG II increased the neurite elongation
up to 162% (control 5 100%, Figs. 1, c, and 2). The length
of the majority of axons was in the range of .350 mm, and
single axons reached distances up to 600 mm. Similarly, the
neurite-promoting capacity of ANG II (1027 M) was also
detectable in neuronal cultures of postnatal rat DRG (data
not shown).
In the presence of drugs selectively interacting with the
two angiotensin receptor subtypes, the outgrowth of neu-
rites was markedly changed. The compound CGP 42112,
an AT2 receptor agonist at higher concentrations (32),
showed comparable effects on neurite regeneration at 1025 M
as obtained with ANG II (Fig. 2). Coincubation with
ANG II did not further increase this response (data not
shown). In the presence of the selective AT2 receptor an-
tagonist, PD123177 (1025 M), the regenerative response
was reduced to control levels (Figs. 1, d, and 2) whereas the
AT1 receptor antagonist, losartan (1025 M), was not able to
block the ANG II–induced neurite elongation (Fig. 2).
In Vivo Effects of ANG II after Optic Nerve Crush. To in-
vestigate  whether the in vitro results apply to CNS lesions
in vivo, we performed an optic nerve crush in adult rats.
Axonal regrowth was quantified by GAP-43 immunohis-
tochemistry, which selectively recognizes an intracellular
phosphoprotein in axonal growth cones and is mandatory
for axon elongation. In control-operated animals, only a
few regenerating fibers were detectable as marked by the
GAP-43 staining and regrowth was limited up to the lesion
site. No unspecific growth stimulation was detectable in
animals receiving the collagen foam immediately after crush
into the vitreous body. GFAP-positive astrocytes marked
the lesion site, in which cystic changes occurred (Figs. 3 a
and 4 a).
To evaluate the regenerative capacity of ANG II, ani-
mals received an ANG II–soaked collagen foam (0.6 nmol),
resulting in the outgrowth of large axon bundles within the
proximal optic nerve. Since the gel foam was placed into
the vitreous body after scleral incision, indirect effects of
ANG II on glial cells or inflammatory cells at the lesion site
resulting in alterations of the nonpermissive nature of the
optic nerve (33) could be excluded. The GAP-43–positive
fibers reached the lesion site and many of them grew over
the lesion site reaching regrowth distances of several milli-
meters (Figs. 3 b and 4 b). The effects of ANG II were
completely abolished by coadministration of the AT2 re-664 AT2 Receptors and Axonal Regeneration
ceptor antagonist, PD 123177 (6 nmol), reducing the re-
generative response to that of control-operated animals
(Fig. 5). On the other hand, the AT1 receptor antagonist,
losartan (6 nmol), did not influence the ANG II–mediated
growth response (Fig. 5).
Schwannoma cells, known to secrete several neuro-
trophic factors (e.g., BDNF), were implanted into the vit-
reous body as an internal control (34), evoking a strong re-
generative response (Fig. 5). The regenerative capacity
observed after ANG II treatment was as pronounced as the
one detected after implantation of these cells, emphasizing
the relevance of this finding.
RT-PCR Analysis. The presence of AT1 (data not
shown) and AT2 receptors (Fig. 6) in the retinal explants
and optic nerves was verified by RT-PCR. In separately
collected tissues from operated animals, both of the angio-
tensin receptor subtypes were detectable. To investigate
whether optic nerve crush evokes alterations in the AT2 re-
ceptor mRNA expression, we determined the AT2 recep-
tor levels in both retinae and optic nerves 3, 8 and 14 d after
Figure 1. (a) Retinal explant (postnatal day 11) in control cultures after 3 d in vitro. Many regenerating, but short neurites were detected. (b) Addition
of BDNF (10 ng/ml) enhanced axonal growth up to 160 6 3%. (c) In the presence of ANG II (1026 M), the number and length of neurites was increased
to comparable amounts (162 6 4%), whereas (d) the AT2 receptor antagonist, PD123177 (1025 M), blocked axonal regrowth (102 6 3%). On the other
hand, the AT1 receptor-antagonist, losartan (1025 M), did not influence the ANG II–induced axonal elongation (data not shown). Bar 5 100 mm.665 Lucius et al.
optic nerve crush with respect to the housekeeping gene
GAPDH. In retinae as well as in optic nerves, we observed a
moderate increase in AT2 receptor mRNA levels after 14 d
by 35 and 22%, respectively (Fig. 6).
Discussion
The salient finding of this study is the observation that
ANG II via its AT2 receptor is able to promote the axonal
regeneration in postnatal retinal explants and DRG in vitro
as well as after optic nerve crush in vivo. The results not
only ascribe a hitherto unknown physiological function to
ANG II as a neurotrophic factor through its AT2 receptor,
but open up a new dimension with respect to our general
understanding of the RAS, one of the most universal endo-
crine and paracrine systems.
In the three-dimensional in vitro culture system used
(29, 30), activation of the AT2 receptor leads to regenera-
tion of neurites from postnatal RGCs comparable to those
from adult animals (35, 36) in their capacity to regenerate.
The finite regenerative capacity of RGCs was reflected in
our control experiments, where the explants were cultured
in serum-free medium and only a limited outgrowth of
neurites was observed. However, the regeneration of neu-
rites can be influenced either by addition of BDNF, a
known neurotrophic factor for RGCs (27), or by cultivat-
ing the explants in the presence of cocultivated astrocytes
(30). Therefore, the RGCs are able to regenerate their ax-
ons if they are supplied with neurotrophic substances. A
similar effect as after BDNF treatment (10 ng/ml) was ob-
served by ANG II application, pointing to a role of this
peptide as a neurotrophic factor.
In addition, ANG II treatment of DRG isolated from
neonatal rats resulted in an AT2 receptor–mediated neurite
extension indicating that the promotion of axonal regener-
ation in response to AT2 receptor stimulation is a general
feature in neuronal cells.
To investigate the effects of ANG II on the axonal elon-
gation of RGCs in vitro, we used, compared with other in
vitro assays, slightly elevated ANG II concentrations (1026 M),
since the retinal explants were cultured in a fibrin clot.
Thus, the ANG II was not freely accessible for the RGCs
and the effective ANG II concentration at the explants dif-
fered from the one in the cell culture medium. Moreover,
it has been shown by Kohler et al. (25) that the ANG II
levels in the retina are 10-fold higher than in the plasma
and that RGCs require higher ANG II concentrations to
be activated (26).
The quantification of the regeneration process was per-
formed by staining against GAP-43. The expression of this
protein is increased after optic nerve lesion (37–39) and
identifies those RGCs that are capable of regenerating their
axons (40). An overexpression of GAP-43 enables neurons
to sprout new terminals (41), whereas the absence of GAP-
43 leads to a poor adherence and unstable lamellar exten-
sions of neurites. These findings point to a role of this pro-
tein in the process of regulated neurite outgrowth during
both development and regeneration (42). Moreover, it has
been shown (43) that the GAP-43 induction is paralleled
by an increased potential of injured CNS neurons to regen-
erate. Therefore, the AT2 receptor–mediated increased
GAP-43 expression after optic nerve crush reflects an in-
creased axonal regeneration of these neurons.
The octapeptide ANG II has been implicated in the pro-
cess of angiogenesis. However, for the following reasons it
is very unlikely that an enhanced blood supply induced by
ANG II is responsible for the axonal regeneration described
here. First, ANG II also induced the axonal elongation of
RGCs and dorsal root ganglion neurons in vitro via its AT2
receptor (Figs. 1 and 2). In these assays, vascularization
events can be excluded. Second, in a study published by
Fernandez et al. (44), it was observed that ANG II induces
vascularization in the cornea. However, even when this
ANG II–induced angiogenesis was not attributed to any
angiotensin receptor subtype, these effects of ANG II can
be explained by stimulation of AT1 receptors since all
known growth-promoting effects of ANG II are mediated
by AT1 receptors. In contrast, all effects presented in this
study in terms of neuronal regeneration are clearly medi-
ated by AT2 receptors since they were completely abol-
ished by PD 123177 and not affected by losartan. In a study
in the rat cremaster muscle (4), it was demonstrated that the
AT1 receptor mediated angiogenic actions in the microcir-
culation, whereas an AT2 receptor stimulation caused an
inhibition of angiogenesis. Le Noble et al. (45) demon-
strated that the angiogenic effects induced by ANG II were
mediated by a “novel” angiotensin receptor since they
could neither be inhibited by PD 123319 nor by losartan.
Investigating the role of ACE (angiotensin-converting en-
zyme) inhibitors and AT1 receptor antagonists, it has been
shown by Gohlke et al. (46) that a treatment with ACE in-
Figure 2. Effect of ANG II on neurite outgrowth of retinal explants
(postnatal day 11). Compared with control cultures, treatment with both,
BDNF (10 ng/ml) and ANG II (1026 M), resulted in increased axonal re-
generation of RGCs. The AT1 receptor antagonist, losartan (1025 M),
had no effect on ANG II-induced neurite extension, whereas treatment
of explants with ANG II and the AT2 receptor antagonist, PD 123177
(1025 M), completely inhibited these effects. The peptide CGP 42112, an
AT2 receptor agonist at 1025 M, entirely mimicked ANG II–mediated ef-
fects (n 5 36 for all experimental groups, mean 6 SEM, *P ,0.05 com-
pared with controls).666 AT2 Receptors and Axonal Regeneration
hibitors but not with losartan increased the capillary density
in the heart. The failure of losartan to exert this effect was
attributed (besides bradykinin) to the chronic overstimula-
tion of AT2 receptors that are left unopposed by an AT1 re-
ceptor antagonism. Finally, if the effects presented in our
manuscript were due to enhanced blood supply, this would
neither result in an increased expression of GAP-43 nor in
an enhanced axonal regrowth beyond the glial scar.
For these reasons, we feel that our statement is justified
attributing the observed AT2 receptor–mediated axonal re-
generation after optic nerve crush to direct effects and not
to indirect vascularization.
In previous studies, we and others have shown that the
AT2 receptor can induce neuronal differentiation in PC12W
cells (6, 14, 15) and neurite outgrowth in the neuroblas-
toma–glioma hybrid cell line NG108-15 (16). Moreover,
the AT2 receptor mRNA is upregulated after axotomy in
sciatic nerves and DRG neurons (12). These findings are
compatible with the hypothesis that ANG II, acting via the
AT2 receptor, represents a factor capable of promoting
neuronal regeneration. AT2 receptors have been implicated
in antiproliferative and differentiation-promoting effects (3,
5, 6), in contrast to the growth-inducing actions of AT1 re-
ceptors, and play a role in tissue repair and wound healing
(10, 37). The latter is of special interest in brain injury and,
indeed, experiments by Viswanathan and Saavedra (11)
have already shown increased tissue AT2 levels after CNS
lesions. Besides this, AT2 receptors are involved in the
Figure 3. Paraffin-embedded sections of optic nerves of control and ANG II–treated animals (GAP-43 staining). (a) In control animals (original mag-
nification: 340), regenerating fibers reached the lesion site (demarcated by two arrows) but rarely grew further. (b) In contrast, animals receiving an ANG
II–soaked gel foam (original magnification: 340) showed regenerating fibers that regularly crossed the lesion site and grew over a distance of several milli-
meters. Higher magnification (right side in b, original magnification: 3640) shows GAP-43–positive fibers (arrowheads) reaching a distance up to 1.6 mm
distal to the lesion site (bar 5 100 mm).667 Lucius et al.
modulation of the proteolytic activity of the extracellular
microenvironment of neurons as suggested by the AT2 re-
ceptor–mediated regulation of serine protease inhibitors in
cultured Schwann cells (48).
These findings gave rise to the hypothesis that AT2 re-
ceptors are also involved in axonal regeneration in the
CNS. Our data show for the first time that AT2 receptor
stimulation indeed leads to enhanced regeneration of axons
from postnatal RGCs and DRG. These effects are totally
abolished in the presence of PD 123177, a selective AT2
receptor antagonist, and are mimicked by agonistic con-
centrations of the selective AT2 receptor agonist, CGP
42112, whereas regeneration is not suppressed by the AT1
receptor antagonist, losartan.
The intracellular signal transduction cascade of AT2 re-
ceptors has not yet been clearly established (for review see
reference 49). One recently reported effect is the inhibition
of mitogen-activated protein (MAP) kinases by dephos-
phorylation (17). Interestingly, an antiapoptotic protein
(Bcl-2; references 50–52) is phosphorylated by MAP ki-
nase, a process which is reversed after AT2 receptor stimu-
lation, resulting in the inactivation of Bcl-2 and the induc-
tion of apoptosis (53).
The question arises as to how a factor suspected to be in-
volved in apoptotic processes can at the same time be con-
tributing to tissue regeneration. This dual role is conceiv-
able in view of the fact that the risk of apoptosis and the
potency for axonal regeneration are closely associated. With
an increasing ability to regenerate, neurons are in danger of
entering programmed cell death (54). If, for example,
mammalian CNS neurons are lesioned close to their cell
bodies, a strong cell body response, a strong regenerative
potency, and, simultaneously, a high risk for cell death are
observed. On the other hand, a distal transection evokes a
weak cell body response resulting in weak regenerative ef-
forts, but the CNS neurons are also somehow protected
from apoptosis. These observations suggest that neuronal
injury initiates a series of molecular events that are initially
identical for both apoptosis and regeneration.
Considering the above-mentioned studies, it is tempting
to speculate that AT2 receptors play a role in either neu-
roregenerative or apoptotic events. Although AT2 recep-
tors can induce apoptosis in different cell types (17, 18, 53),
an increasing body of evidence demonstrates an AT2 recep-
tor–mediated promotion of regenerative actions in both
neuronal and nonneuronal cells (our data and references
10, 12, 47). It appears now that the well-known growth-
promoting effects of the AT1 receptor, which can engender
neuroplastic as well as pathological structural changes in
Figure 4. Camera-lucida projections from serial sections of paraffin-
embedded and GAP-43–stained optic nerves. The lesion site is demar-
cated by two arrows. In control animals (a), only few fibers grew over the
lesion, whereas in animals receiving the ANG II gel foam (b), numerous
axons crossed the lesion site and regenerated over a distance of several
millimeters. ANG II increased the number of GAP-43–positive axons in
the proximal optic nerve stump compared with controls (b). The AT2 re-
ceptor–mediated regeneration was completely abolished by the selective
AT2 receptor antagonist, PD 123177 (see Fig. 6), whereas the selective
AT1 receptor antagonist, losartan, had no effect (see Fig. 6).
Figure 5. Measurement of regrowth of lesioned axons in the optic
nerve. Evaluations were made in a blinded fashion by number-coded
GAP-43–positive serial sections. Only rats with regenerative fibers/
sprouts distal to the lesion were included in this analysis. The length of re-
generated axons was measured by a video image processing program
(Analysis; SIS) from the distal end of the lesion site. Compared with con-
trol-operated animals, the application of ANG II evoked an increase in
the regenerative response that was completely suppressed by costimula-
tion with the AT2 receptor antagonist, PD 123177, but not by the AT1
receptor antagonist, losartan (n 5 5 for all experimental groups, mean 6
SEM, *P ,0.05 compared with controls).668 AT2 Receptors and Axonal Regeneration
several organs, are counteracted within the RAS itself by
growth arrest, differentiation, and tissue repair, effected
through the AT2 receptor, and that a (disturbed) balance
between the opposing actions of these two receptors deter-
mines the net effects of the RAS in a given disease situa-
tion.
Our findings on the neurotrophic actions of the AT2
receptor may provide a basis for the design of new, recep-
tor-directed therapeutic strategies in the failure of axonal
regeneration in the mammalian CNS. This is of particular
interest considering the current difficulties in applying neu-
rotrophic factors after nerve fiber damage. Moreover, AT2-
mediated tissue regeneration may not be confined to ax-
onal regrowth but may constitute a general phenomenon
to be exploited by therapeutic intervention. The clinical
relevance of this approach becomes apparent with the in-
creasing use of AT1 receptor antagonists as antihypertensive
drugs in, as of this time, more than two million patients
worldwide. Since AT2 receptors are unmasked and ANG II
levels are increased by AT1 receptor antagonists, part of the
organ-protective actions of these drugs might be ascribed
to an agonistic action of ANG II at the AT2 receptor site.
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